The Priority Review

Tag

TGCT

1 story

Stories

  1. Approvals

    Abbisko's PIMJETMI receives U.S. FDA approval for TGCT

    The U.S. FDA approved PIMJETMI as a systemic treatment for adults with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection may cause worsening functional limitation or severe morbidity. The approval follows earlier approvals in China, Canada and Switzerland and is based on the Phase III MANEUVER study showing a 56% objective response rate versus 3% for placebo.